Xeris Biopharma Holdings, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Vanguard Capital Management has reported beneficial ownership of 5% of Xeris Biopharma Holdings Inc. common stock as of June 30, 2026.
NASDAQ
The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Xeris Biopharma Holdings Inc. following an internal realignment.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in Xeris Biopharma Holdings Inc.